A post market clinical follow up study of Sodium Hyaluronate 0.2% Eye Drops
Phase 4
Completed
- Conditions
- Health Condition 1: H579- Unspecified disorder of eye and adnexa
- Registration Number
- CTRI/2024/02/062929
- Lead Sponsor
- Amanta Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 54
Inclusion Criteria
Subjects who are able to give voluntary, written informed consent to participate in this study.
Subjects who experience eye dryness, Eye Soreness/ burning, Irritative Sensation, Eye fatigue, contact lens caused dryness, discomfort of eyes due to the continuous use of computer/ TV/
exposed pollution/ dry environment
Exclusion Criteria
Anyone with known allergic reaction to Sodium Hyaluronate 0.2% Eye Drops.
Subjects with existing eye infection
History of ocular surgery. History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time
Patients participating in any another clinical trial during study
Pregnant/lactating women during study period.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method